Valuation: GlaxoSmithKline Pharmaceuticals Limited

Market Cap 413B 4.33B 3.78B 3.49B 3.22B 6.12B 6.22B 41.7B 16.38B 203B 16.24B 15.89B 699B P/E 2027 *
35.8x
P/E 2028 * 31.5x
Enterprise Value 413B 4.33B 3.78B 3.49B 3.22B 6.12B 6.22B 41.7B 16.38B 203B 16.24B 15.89B 699B EV / Sales 2027 *
9.84x
EV / Sales 2028 * 8.88x
Free-Float
24.36%
Yield 2027 *
1.21%
Yield 2028 * 1.21%

Last Transcript: GlaxoSmithKline Pharmaceuticals Limited

1 day-0.31%
1 week+0.81%
Current month-0.63%
1 month+10.98%
3 months+3.19%
6 months+2.57%
Current year-1.43%
1 week 2,370.65
Extreme 2370.65
2,460
1 month 2,088
Extreme 2088
2,508.35
Current year 2,088
Extreme 2088
2,715.15
1 year 2,088
Extreme 2088
3,266.95
3 years 1,376.5
Extreme 1376.5
3,515.95
5 years 1,228
Extreme 1228
3,515.95
10 years 1,020
Extreme 1020
3,515.95
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2022
Director of Finance/CFO - 01/04/2026
Chief Tech/Sci/R&D Officer - 08/07/2024
Director TitleAgeSince
Director/Board Member 64 07/04/2017
Chairman 73 01/04/2019
Director/Board Member 59 18/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%+0.81%-26.20%+74.04% 4.34B
-2.57%-1.30%+49.81%+161.38% 1,085B
-1.05%-1.14%+62.58%+60.73% 624B
-1.45%-3.36%+26.25%+83.05% 442B
+0.33%-1.17%+27.98%+26.90% 332B
-3.89%-11.22%+20.78%+26.07% 277B
-0.02%-2.85%+25.27%+44.88% 282B
+0.66%-1.42%-29.26%-39.30% 217B
-0.59%-1.28%+20.43%+60.97% 196B
-3.80%+0.08%+13.24%+71.37% 167B
Average -1.33%-1.57%+19.09%+57.01% 362.63B
Weighted average by Cap. -1.61%-1.06%+34.92%+81.13%

Financials

2027 *2028 *
Net sales 41.94B 440M 385M 355M 328M 622M 632M 4.24B 1.66B 20.66B 1.65B 1.62B 71.03B 46.45B 487M 426M 393M 363M 689M 700M 4.7B 1.84B 22.88B 1.83B 1.79B 78.67B
Net income 11.51B 121M 106M 97.41M 89.97M 171M 174M 1.16B 457M 5.67B 453M 443M 19.5B 12.87B 135M 118M 109M 101M 191M 194M 1.3B 511M 6.34B 507M 496M 21.8B
Net Debt - -
Logo GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Employees
3,103
Date Price Change Volume
10/07/26 2,435.50 -0.31% 2,897
09/07/26 ₹2,443.10 +1.38% 3,459
08/07/26 ₹2,409.90 +0.29% 6,361
07/07/26 ₹2,402.90 +0.10% 4,333
06/07/26 ₹2,400.60 +0.33% 183,948
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,435.50INR
Average target price
2,969.75INR
Spread / Average Target
+21.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock